Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61202 |
TDO-IN-1
|
Others | Others |
TDO-IN-1 是一种具有口服活性、有效性和选择性的色氨酸 2,3-双加氧酶 (TDO)抑制剂 ,对吲哚胺-2,3-双加氧酶 具有抑制作用。TDO-IN-1 具有抗肿瘤活性, 能够通过逆转肿瘤组织的局部免疫耐受来发挥作用。 | |||
T11623 |
IDO/TDO-IN-1
|
Others | Others |
IDO/TDO-IN-1 is an orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50s: 9.7 and 47 nM). | |||
T61385 |
IDO1/TDO-IN-1
|
||
IDO1/TDO-IN-1 (30) is a highly effective inhibitor that targets both IDO1 and TDO enzymes with uncompetitive (Ki = 0.23 μM) and competitive (Ki = 0.73 μM) mechanisms, respectively. This compound, IDO1/TDO-IN-1 (30), exhibits a significant capacity to induce cell apoptosis via the potential mitochondria-mediated Bcl-2/Bax pathway [1]. | |||
T78795 |
IDO1/TDO-IN-6
|
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO1/TDO-IN-6(compound 11)为IDO1/TDO双重抑制剂,其IC50值分别为2.25 μM和2.89 μM。在抑制IDO1和TDO方面,其Ki值分别为1.9 μM和3.1 μM。IDO1/TDO-IN-6适用于癌症与免疫学领域的研究。 | |||
T60499 |
IDO1/TDO-IN-2
|
||
IDO1/TDO-IN-2 (Compound 1) 是有效的IDO1/TDO 双重抑制剂,IC50s 分别为 0.1 和 0.07 μM,具有癌症研究的潜力。 | |||
T61140 |
IDO1/TDO-IN-3
|
||
IDO1/TDO-IN-3 is a powerful inhibitor targeting IDO1 and TDO enzymes. It displays noteworthy effectiveness against IDO1 (IC50: 0.005 μM) and TDO (IC50: 0.004 μM). Additionally, IDO1/TDO-IN-3 demonstrates considerable in vivo anti-tumor properties while exhibiting no apparent toxicity [1]. | |||
T60318 |
IDO1/TDO-IN-4
|
||
IDO1/TDO-IN-4 显示出对 IDO1 (IC50 = 3.53 μM) 和 TDO (IC50 = 1.15 μM) 的有效抑制作用,并且具有可接受的安全性和药代动力学特性。IDO1/TDO-IN-4 可与 IDO1 形成氢键,与 TDO 产生 π-π 堆积相互作用。 IDO1/TDO-IN-4 可用于抑郁症以及炎症引起的抑郁症的研究。 | |||
T74536 | IDO/Tubulin-IN-2 | ||
IDO/Tubulin-IN-2 (HT2) 是一种对TDO和微管蛋白 (tubulin)展现出高效抑制作用的化合物。该抑制剂对多种癌细胞系(包括U87、HepG2、A549、HCT-116和LO2)均表现出强抗肿瘤活性,其半抑制浓度(IC50)分别为0.43、0.036、0.041、0.095和1.04 μM,有效提升了抗肿瘤效果。 | |||
T72056 |
KYN-101
|
||
KYN-101是一种高效、选择性的芳香烃受体(AHR)合成拮抗剂,在人HepG2 DRE 荧光素酶报告基因检测中IC50为22 nM,在小鼠Hepa1 Cyp-luc 检测中IC50为23 nM。KYN-101逆转IDO/TDO 介导的肿瘤进展,提高PD-1阻断B16 IDO 荷瘤小鼠和表达内源性高水平IDO 的CT26结直肠癌模型的疗效。 |